In January 2024, a human being received a neural implant whose firmware is remotely updatable and whose operational data resides on corporate servers in jurisdictions not bound by the patient's national health law. Medicine has not updated its diagnostic frameworks, liability structures, or clinical protocols in response. This paper argues that gap is not a minor regulatory oversight. It is a structural failure with immediate consequences for a small but growing patient population, and a predictable problem for a much larger one as brain-computer interface (BCI) technology scales.The failure is not only legal. Laws protect what legal systems can identify. Clinical systems respond to what diagnostic frameworks can name. Until medicine develops a precise vocabulary for neuro-digital harm, harm originating in the interaction between neural tissue and external technological infrastructure, neither legal nor clinical protection can function well. A patient whose involuntary movements were caused by a firmware update cannot be protected by neurorights legislation if the neurologist at the bedside has no protocol for establishing that firmware caused the movements.This gap carries equity dimensions that existing frameworks have underweighted. Neural augmentation technologies will, in their early deployment cycles, be accessible primarily to high-income populations in well-resourced health systems. The stratification this creates is not merely economic. Patients with active neural interfaces will present to clinicians with cognitive and neurological baselines that differ structurally from unaugmented patients, and they will do so first in contexts where clinical infrastructure is least equipped to respond. The problem is not only one of access to devices. It is one of access to protocols: the structured clinical decision logic, analogous to the WHO IMCI guidelines that have successfully standardized care in low-resource settings, that tells a practitioner what to do when a situation falls outside their training. The global health governance implications of this trajectory have not been adequately addressed by existing frameworks, including UNESCO's 2023 Declaration on the Ethics of Neuroscience and Neurotechnology, the OECD's 2023 Recommendation on Responsible Innovation in Neurotechnology, or WHO's 2021 guidance on AI for health.This paper proposes two contributions. The Synaptic Split Framework (SSF) is a formal diagnostic architecture distinguishing Type I Biological Neurological Dysfunction from Type II Neuro-Digital Disruption, expressed as a decision model with explicit input variables, classification logic, and uncertainty handling. The Technology Audit Protocol (TAP) is an operationalized clinical procedure specifying required data types, interoperability standards, positive and negative threshold logic, and data access barrier classifications for patients with active BCIs presenting with neurological or psychiatric symptoms. Both proposals are anticipatory. Their value is preparatory: medicine needs formal conceptual infrastructure before the patient population they describe becomes routine. Critically, that infrastructure must be designed with deployment constraints in mind from the start, including the offline-first, low-connectivity environments where much of the world’s clinical decision-making actually happens. Frameworks: Synaptic Split Framework (SSF), Technology Audit Protocol (TAP), Neuro-Digital Response Unit (NDRU)Standards: HL7 FHIR, SNOMED CT, NIST CVE, FDA SaMD, UNESCO 2023, OECD 2023, WHO AI for Health 2021Keywords: neurorights, brain-computer interfaces, cognitive sovereignty, neuro-digital medicine, adversarial ML, closed-loop neural stimulation, BCI liability, neural data governance, global health equity
Amrin Majumder (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: